4,643,430 Shares in Pharvaris N.V. $PHVS Purchased by venBio Partners LLC

Key Points

• venBio Partners acquired 4.64 million Pharvaris shares worth approximately $160.6 million, representing about 7.1% of the company and making Pharvaris its largest holding. Several other institutional investors also initiated or increased positions.
• Pharvaris shares recently traded at $35.32, down $1.68, with a market capitalization of about $2.31 billion. The company missed quarterly earnings expectations, reporting a loss of $0.81 per share versus the estimated $0.75 loss.
• Analysts remain broadly positive, with a consensus “Moderate Buy” rating and an average price target of $51.08, although insiders sold 121,325 shares worth roughly $4.27 million over the past three months.

venBio Partners LLC acquired a new stake in Pharvaris N.V. (NASDAQ:PHVS - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 4,643,430 shares of the company's stock, valued at approximately $160,569,809. Pharvaris comprises about 0.0% of venBio Partners LLC's holdings, making the stock its biggest holding. venBio Partners LLC owned approximately 7.10% of Pharvaris as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in PHVS. Public Employees Retirement System of Ohio purchased a new stake in shares of Pharvaris during the second quarter valued at approximately $196,000. Seven Fleet Capital Management LP raised its stake in Pharvaris by 144.6% in the 2nd quarter. Seven Fleet Capital Management LP now owns 774,501 shares of the company's stock valued at $26,782,000 after purchasing an additional 457,804 shares during the last quarter. Bank of America Corp DE acquired a new position in shares of Pharvaris during the second quarter worth about $4,800,000. Elmind Capital LP acquired a new stake in Pharvaris in the second quarter valued at about $18,180,435. Finally, 5AM Venture Management LLC acquired a new stake in Pharvaris in the 2nd quarter worth about $27,581,008.

Pharvaris Price Performance

PHVS traded down $1.68 during trading on Friday, hitting $35.32. The stock had a trading volume of 478,862 shares, compared to its average volume of 337,589. The firm has a market cap of $2.31 billion, a price-to-earnings ratio of -11.58 and a beta of -2.31. Pharvaris N.V. has a one year low of $20.65 and a one year high of $38.13. The company has a 50 day moving average price of $34.56 and a 200-day moving average price of $30.71.

Pharvaris (NASDAQ:PHVS - Get Free Report) last announced its earnings results on Wednesday, August 12th. The company reported ($0.81) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.06). As a group, sell-side analysts predict that Pharvaris N.V. will post -3.15 EPS for the current fiscal year.

Insiders Place Their Bets

In other Pharvaris news, insider Anna Nijdam sold 2,670 shares of the company's stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $30.87, for a total transaction of $82,422.90. Following the completion of the sale, the insider directly owned 46,275 shares in the company, valued at $1,428,509.25. This represents a 5.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Anne Lesage sold 30,703 shares of the company's stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $35.49, for a total transaction of $1,089,649.47. Following the completion of the transaction, the insider directly owned 93,969 shares of the company's stock, valued at approximately $3,334,959.81. The trade was a 24.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 121,325 shares of company stock worth $4,270,425 in the last three months. 11.84% of the stock is owned by company insiders.

Analysts Set New Price Targets

PHVS has been the topic of several recent research reports. New Street Research set a $60.00 price objective on shares of Pharvaris in a research report on Friday, August 14th. Wells Fargo & Company began coverage on Pharvaris in a research report on Wednesday, July 15th. They issued an "overweight" rating and a $55.00 price target for the company. Citigroup reaffirmed a "market outperform" rating on shares of Pharvaris in a report on Thursday, August 13th. Citizens Jmp increased their price target on Pharvaris from $74.00 to $75.00 and gave the stock a "market outperform" rating in a research report on Thursday, August 13th. Finally, Wall Street Zen cut shares of Pharvaris from a "hold" rating to a "sell" rating in a research note on Saturday, July 18th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $51.08.

Pharvaris Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company's core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company's lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source